Drugs / CX-2029
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03543813 | Jun 2018 → Jun 2023 | diffuse large B-cell lymphoma, esophageal cancer, head and neck cancer, non-small cell lung carcinoma | CytomX Therapeutics | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CX-2029 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03543813 ↗ |